| NK cell-based cancer immunotherapy: from basic biology to clinical development | 2021/01/06 | English | 291 |
| An evolving new paradigm: endothelial cells – conditional innate immune cells | 2013/08/22 | English | 279 |
| Next generation of immune checkpoint inhibitors and beyond | 2021/03/19 | English | 279 |
| Regulation of PD-L1 expression in the tumor microenvironment | 2021/01/07 | English | 271 |
| Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors | 2016/10/04 | English | 268 |
| Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | 2017/02/22 | English | 265 |
| Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy | 2019/12/01 | English | 264 |
| Roles of METTL3 in cancer: mechanisms and therapeutic targeting | 2020/08/27 | English | 262 |
| Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel | 2018/03/02 | English | 260 |
| M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma | 2020/01/08 | English | 259 |
| CircRNAs in cancer metabolism: a review | 2019/09/04 | English | 258 |
| Abscopal effect of radiotherapy combined with immune checkpoint inhibitors | 2018/08/16 | English | 257 |
| Diverse functions of miR-125 family in different cell contexts | 2013/01/15 | English | 251 |
| Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein | 2017/02/01 | English | 250 |
| LSD1/KDM1A inhibitors in clinical trials: advances and prospects | 2019/12/01 | English | 249 |
| New development in CAR-T cell therapy | 2017/02/21 | English | 249 |
| The role of stromal cancer-associated fibroblasts in pancreatic cancer | 2017/03/28 | English | 247 |
| cGAS-STING, an important pathway in cancer immunotherapy | 2020/06/22 | English | 245 |
| Emerging therapies for small cell lung cancer | 2019/05/02 | English | 244 |
| Targeting the IDO1 pathway in cancer: from bench to bedside | 2018/08/02 | English | 241 |
| Nanotechnology in cancer diagnosis: progress, challenges and opportunities | 2019/12/01 | English | 239 |
| Challenges and advances in clinical applications of mesenchymal stromal cells | 2021/02/12 | English | 237 |
| Cancer vaccines as promising immuno-therapeutics: platforms and current progress | 2022/03/18 | English | 231 |
| Lessons learned from the blockade of immune checkpoints in cancer immunotherapy | 2018/02/27 | English | 227 |
| A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer | 2013/01/04 | English | 226 |
| Tumor neoantigens: from basic research to clinical applications | 2019/09/06 | English | 225 |
| Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | 2016/05/27 | English | 225 |
| Applications of patient-derived tumor xenograft models and tumor organoids | 2020/01/07 | English | 222 |
| Cancer-associated adipocytes: key players in breast cancer progression | 2019/09/10 | English | 219 |
| The roles of metallothioneins in carcinogenesis | 2018/08/23 | English | 219 |